Article Sidebar

PDF
Date Published: 15/01/2024
Abstract Views: 658
Views PDF: 336
DOI: https://doi.org/10.51298/vmj.v534i1.8060
Issue
Vol. 534 No. 1 (2024)
Section
Các bài báo
How to Cite
Đỗ , M. Q. ., Đào , Đức T. ., Trần , T. K. T. ., & Cao , Đình H. . (2024). PREVALANCE OF METABOLIC ASSOCIATED FATTY LIVER DISEASE IN DIABETES TYPE 2. Vietnam Medical Journal, 534(1). https://doi.org/10.51298/vmj.v534i1.8060

PREVALANCE OF METABOLIC ASSOCIATED FATTY LIVER DISEASE IN DIABETES TYPE 2

Minh Quân Đỗ , Đức Tiến Đào , Thị Khánh Tường Trần , Đình Hưng Cao

Main Article Content

Abstract

Purpose: investigate the prevalence of metabolic associated fatty liver disease (MAFLD) in diabetes type 2, relevant factors and the prevalence of co-infection of hepatitis B, C and alcohol abuse among the MAFLD patients. Method: Cross-sectional study was designed to asses 120 diabetes type 2 cases between August 1st 2022 to April 30th 2023 at 175 military hospital. Metabolic associated fatty liver disease is diagnosed by the FibroScan – CAP compact 530 device. The data collected was analyzed by R 3,4,3 software. Results: The prevalence of metabolic associated fatty liver disease among diabetes is 62,5%, the patient diagnosed with metabolic associated fatty liver disease has a higher Body Mass Index (BMI) (p<0,001), higher Triglyceride concentration (p<0,05). The prevalence of co-infection of hepatitis B, C and alcohol abuse among the patient diagnosed with metabolic associated fatty liver disease is 29,3%, 8% and 28%. Conclusions: this research is conducted to raise the awareness in screening metabolic associated fatty liver disease among diabetes. The patient diagnosed with metabolic associated fatty liver should be screened for co-infection of hepatitis B, C and alcohol abuse.

Article Details

References

1. Cheng K. L., Wang S. W., Cheng Y. M., Hsieh T. H., et al. (2023), "Prevalence and clinical outcomes in subtypes of metabolic associated fatty liver disease". J Formos Med Assoc.
2. Eslam M., Newsome P. N., Sarin S. K., Anstee Q. M., et al. (2020), "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement". J Hepatol, 73(1), pp. 202-209.
3. Eslam M., Sanyal A. J., George J., và International Consensus P. (2020), "MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease". Gastroenterology, 158(7), pp. 1999-2014 e1.
4. Guan C., Fu S., Zhen D., Yang K., et al. (2022), "Metabolic (Dysfunction)-Associated Fatty Liver Disease in Chinese Patients with Type 2 Diabetes from a Subcenter of the National Metabolic Management Center". J Diabetes Res, 2022, pp. 8429847.
5. Huang J. F., Tsai P. C., Yeh M. L., Huang C. F., et al. (2023), "Community-centered Disease Severity Assessment of Metabolic Dysfunction-associated Fatty Liver Disease". J Clin Transl Hepatol, 11(5), pp. 1061-1068.
6. Le N. T. D., Dinh Pham L., và Quang Vo T. (2017), "Type 2 diabetes in Vietnam: a cross-sectional, prevalence-based cost-of-illness study". Diabetes Metab Syndr Obes, 10, pp. 363-374.
7. Lu J., Hou X., Tu H., Tang Z., et al. (2017), "Chronic hepatitis B virus infection status is more prevalent in patients with type 2 diabetes". J Diabetes Investig, 8(4), pp. 619-625.
8. Ndako J. A., Owolabi A. O., Olisa J. A., Akinwumi J. A., et al. (2020), "Studies on the prevalence of Hepatitis C virus infection in diabetic patients attending a tertiary health-care facility South-west Nigeria". BMC Infect Dis, 20(1), pp. 664.